Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patient's blood; and AVISE APS that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE Anti-Histone, a test for autoantibodies to histone proteins; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP, a biomarker-driven RA prognostic test. Further, the company offers AVISE SLE Monitor, a blood test that employs CB-CAPs technology; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop T-Cell biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

Exagen Inc.

In a report released today, Anita Soni from CIBC reiterated a Buy rating on IAMGOLD, with a price target of $19.00. According to TipRanks, Soni is ...

CIBC Sticks to Their Buy Rating for IAMGOLD (IAG)

In a report released yesterday, Michael Siperco from RBC Capital maintained a Buy rating on IAMGOLD, with a price target of $17.00. According to Ti...

IAMGOLD (IAG) Receives a Rating Update from a Top Analyst

Stifel Nicolaus analyst Ingrid Rico maintained a Buy rating on IAMGOLD today and set a price target of C$28.00. Rico covers the Basic Materials sec...

IAMGOLD (IAG) Receives a Buy from Stifel Nicolaus

IAMGOLD Corp ( ($IAG) ) has released its Q3 earnings. Here is a breakdown of the information IAMGOLD Corp presented to its investors. IAMGOLD Corpo...

IAMGOLD Reports Strong Q3 2025 Performance

AxoGen ( ($AXGN) ) has released its Q3 earnings. Here is a breakdown of the information AxoGen presented to its investors. Axogen, Inc. is a leadin...

Axogen Reports Strong Q3 2025 Results, Raises Guidance

AxoGen (($AXGN)) has held its Q3 earnings call. Read on for the main highlights of the call. AxoGen’s recent earnings call conveyed a generally pos...

AxoGen’s Earnings Call Highlights Robust Growth and Strategic Progress

Lake Street analyst Frank Takkinen reiterated a Buy rating on AxoGen today and set a price target of $30.00. The company’s shares opened today at $...

Lake Street Remains a Buy on AxoGen (AXGN)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Inotiv (NOTV – Research Report) and Exagen (XGN – Re...

Current Quarter	$-0.16	Next Quarter	$-0.14
Current Year	$-0.74	Next Year	$-0.5
QoQ Growth	+12.5%	YoY Growth	+32.4%
3Y EPS CAGR	+20.9%	Target Price	$15.43
Consensus	Buy	Upside	+102.8%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	XGN	$7.61	-2.06%	219.88K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	XGN	$7.61	-2.1%	219.88K
3
4
5
6

XGN

XGN

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Exagen Inc. Data in Excel

Get Exagen Inc. Data in Excel